Previous 10 | Next 10 |
REDWOOD CITY, CA / ACCESSWIRE / February 19, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Third Quarter Fiscal Year 2024 Fina...
2024-02-14 09:54:39 ET More on Biotricity Seeking Alpha’s Quant Rating on Biotricity Historical earnings data for Biotricity Financial information for Biotricity Read the full article on Seeking Alpha For further details see: Biotricity rep...
Company continues its shift to subscription-based revenue, prioritizing margin improvement and operational efficiency enhancements, on the path to breakeven Management to announce Third Quarter Fiscal 2024 Results at market close on February 20, 2024 REDWOOD CITY, CA / ACCESSWIRE / Febr...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
Company's growing data ecosystem supports the development of large data models for its future predictive technologies and Cardiac AI cloud platform Company has analyzed over 360 Billion heartbeats and helped diagnose over 200,000 patients Company is now focused on building predictive A...
2023-11-14 21:25:06 ET Biotricity, Inc. (BTCY) Q2 2024 Earnings Conference Call November 14, 2023, 06:00 PM ET Company Participants Debra Chen - IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Davin - H....
2023-11-14 17:36:42 ET More on Biotricity Biotricity posts $14M revenue run rate in August Seeking Alpha’s Quant Rating on Biotricity Historical earnings data for Biotricity Financial information for Biotricity For further details see: Biot...
Company reports Q2-FY24 revenue grew by 21.4% YOY to $2.9 million; continuing to advance toward positive cashflow Recurring technology fees, customer device sales, remain on an upward trend Reduced SG&A to $3.5 million, down 22% compared to same period last year Gross margins i...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Biotricity Inc. (BTCY) is expected to report $-0.34 for Q2 2024
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, CA / ACCESSWIRE / June 12, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announces the highly anticipated launch of its di...
Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-...
REDWOOD CITY, CA / ACCESSWIRE / June 4, 2024 / Biotricity Inc.] (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is thrilled to announce that the majority of its existing P...